Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Marqibo plus Rituximab in Relapsed/Refractory Aggressive NHL
NCT01851551Phase 2Completed
- Sponsor
- Acrotech Biopharma Inc
- Start
- Sep 2001
- Primary completion
- Apr 2004
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of vincristine sulfate liposome in diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL), sponsored by Acrotech Biopharma Inc. Primary endpoint: Objective Response Rate at 24 weeks. Started Sep 2001; status: completed.
02
Drugs
vincristine sulfate liposome
03
Conditions
diffuse large B-cell lymphoma (DLBCL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT01851551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01851551.